Raleigh Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Raleigh Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.73K	Buy	+34	New	+$5.04K	﹤0.01%	394
2023 Q2	–	Sell	-66	Closed	-$6.68K	–	890
2023 Q1	$6.68K	Buy	66 +29	+78%	+$3.02K	﹤0.01%	576
2022 Q4	$4.42K	Buy	37 +10	+37%	+$1.17K	﹤0.01%	566
2022 Q3	$3K	Buy	+27	New	+$2.74K	﹤0.01%	600

Other funds holding NBIX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

PBBUPS

PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Amalgamated Bank New York $14.5B AUM 44.3% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Raleigh Capital Management's NBIX Position: Q2 2026 in Review

Raleigh Capital Management opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 34 shares worth $5.73K. The stake represents ﹤0.01% of the portfolio and ranks #394 among its holdings. This is a return to the name: Raleigh Capital Management previously reported a position in NBIX as recently as Q1 2023.

Raleigh Capital Management first reported a position in NBIX in Q3 2022 and has held it in 4 quarters since. The position peaked at $6.68K in Q1 2023. 154 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Raleigh Capital Management held 34 shares of Neurocrine Biosciences worth $5.73K as of Q2 2026.
Neurocrine Biosciences was a new Raleigh Capital Management position in Q2 2026.
Neurocrine Biosciences made up ﹤0.01% of Raleigh Capital Management's portfolio in Q2 2026, its #394 holding.
Raleigh Capital Management first reported a position in Neurocrine Biosciences in Q3 2022 and has held it in 4 quarters since.
Raleigh Capital Management's Neurocrine Biosciences position peaked at $6.68K in Q1 2023.
154 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Raleigh Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.